NDUFC1
ENSG00000109390
Target class
Enzyme
Chromosome
4
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- KFYI
- Target name
- NDUFC1
- Gene name
- NADH:ubiquinone oxidoreductase subunit C1
- Gene symbol
- NDUFC1
- Protein name
- NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial (Complex I-KFYI) (CI-KFYI) (NADH-ubiquinone oxidoreductase KFYI subunit)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 84.75
- Tissue specificity (Gini)
- 0.162
- Tissue specificity (tau)
- 0.423
- KEGG gene identifiers
- hsa:4717
- Protein interaction confidence
- 0.938805
- Protein interaction partners
- 77
- R-HSA-611105
- R-HSA-6799198
- End position
- 139302564
- Start position
- 139266880
- Chromosome
- 4
- Strand
- Reverse
- Mitochondrion inner membrane
- Single-pass membrane protein
- Matrix side .
- Mitochondria
- Tissue specificity (tau)
- 0.42261
- Expression inequality (Gini)
- 0.161878
Expression in transcripts per million
- Heart - Atrial Appendage
- 84.75
- Heart - Left Ventricle
- 84.02
- Testis
- 83.49
- Pituitary
- 78.9
- Kidney - Medulla
- 74.95
Expression in transcripts per million
- Heart - Atrial Appendage84.75
- Heart - Left Ventricle84.02
- Testis83.49
- Pituitary78.9
- Kidney - Medulla74.95
- Adrenal Gland71.29
- Muscle - Skeletal69.63
- Thyroid68.64
- Brain - Cerebellar Hemisphere66.89
- Artery - Aorta64.88
- Artery - Coronary57.91
- Artery - Tibial56.73
- Ovary55.78
- Kidney - Cortex55.56
- Brain - Frontal Cortex (BA9)55.29
- Brain - Cerebellum54.85
- Brain - Nucleus accumbens (basal ganglia)51.65
- Brain - Hypothalamus50.87
- Fallopian Tube50.69
- Colon - Sigmoid50.11
- Uterus49.78
- Cervix - Endocervix49.13
- Esophagus - Mucosa49.06
- Cervix - Ectocervix48.67
- Prostate48.5
And 29 more, listed on the interactive page.
Biological processes
- GO:0006120
- GO:0005739
- GO:0005743
- GO:0045271
Molecular functions
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor